Atai Life Sciences N.V. (ATAI)

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourt...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dose...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topl...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.

Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.2...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwr...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The company may also grant the underwriter a 30-day option to purch...